Compare Moody's Corporation (MCO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Revvity Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Moody's Corporation is far larger — about 4.7× Revvity Inc's market cap, and Moody's Corporation pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Revvity Inc for 12 Days on average.
| MCO | RVTY | |
|---|---|---|
Market Cap | $79.44B | $16.98B |
Volume | 526,684 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $539.61 | $157.36 |
52-Week Low | $412.23 | $82.26 |
Typical Hold Time | 132 Days | 12 Days |
Enterprise Value | $85.46B | $19.30B |
Dividend Yield | 0.9% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals including 34.25% net income margin and 80.15% ROE. Recent earnings beats and a consensus price target of $536.40 suggest upside potential. The company announced a minority stake in PhilRatings and a new credit risk model with Allvue, expanding its Asia-Pacific presence and product offerings.
Outlook is positive given consistent earnings growth and strategic expansions, though high valuation multiples and bearish technical indicators near-term pose risks. Analyst consensus is bullish with 56% buy ratings, but investors should monitor debt levels and macroeconomic sensitivity.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
